Xiang, S., Gu, H., Jin, L., Thorne, R
Managing anemia in people taking semaglutide often involves dietary changes and supplementation
When stratified by comparator groups, the pooled estimate was most favorable in monotherapy trials versus placebo (SMD 2.41, 95% CI 4.43 to 0.39), whereas the add-on designs versus the same background treatment (SMD 0.65, 95% CI 1.85 to 0.55), head-to-head comparisons versus another drug (SMD 0.19, 95% CI 0.84 to 0.45), and add-on designs versus placebo (SMD 0.65, 95% CI 1.35 to 0.06) showed more modest estimates and did not provide clear evidence of a between-group difference overall (p=0.21)
The BCBS changes meant that Wegovy prescriptions for obesity or overweight conditions would no longer receive coverage in affected plans
Customer service has been great
What Role Does GLP-1 Normally Have In Our Body